Search results for "Rheum"

showing 10 items of 1028 documents

The skin in autoimmune diseases-Unmet needs.

2016

Treatment of skin manifestations in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and dermatomyositis (DM) is based on the results of only few randomized controlled trials. The first-line treatment for disfiguring and widespread cutaneous involvement in SLE is antimalarials, but some patients are therapy resistant. Recently, the monoclonal antibody belimumab was approved for SLE as an adjunct therapy for patients with autoantibody-positive disease who despite standard therapy show high disease activity, intolerance of other treatments, or an unacceptably high need for corticosteroids. However, a validated skin score has not been used to confirm the efficacy of belimumab on m…

medicine.medical_specialtyImmunologyMucocutaneous zoneDiseaseSeverity of Illness IndexDermatomyositislaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineImmunology and AllergyHumansLupus Erythematosus SystemicRandomized Controlled Trials as TopicSkin030203 arthritis & rheumatologyAutoimmune diseaseWound HealingScleroderma Systemicintegumentary systembusiness.industryDermatomyositismedicine.diseaseDermatologyBelimumabDiscontinuationImmunologybusinessProgressive diseaseImmunosuppressive Agentsmedicine.drugAutoimmunity reviews
researchProduct

Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias

2015

International audience; Background The effectiveness of intra-articular hyaluronic acid (IAHA) injection for knee osteoarthritis (KOA) is debated.Objectives To evaluate the effect of IAHA for patients with KOA by analysing data from trials of IAHA versus placebo with low risk of bias, to provide the highest level of evidence.Methods A systematic review and meta-analysis was conducted. Randomised controlled trials (RCTs) with a low risk of bias (adequate randomisation and concealment and double-blind design) that investigated IAHA versus placebo (saline solution) injection were eligible. The primary efficacy measure was pain intensity and secondary outcome function at 3 months. The treatment…

medicine.medical_specialtyImmunologyOsteoarthritisPlacebo[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system03 medical and health sciences0302 clinical medicineRheumatologyOsteoarthritismedicineForest plotImmunology and AllergyKneeTreatment effect1506030212 general & internal medicine10. No inequalityHyaluronan030203 arthritis & rheumatology[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systembusiness.industryEvidence-based medicinemedicine.disease3. Good healthTreatmentStudy heterogeneity[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemOutcomes researchMeta-analysisPhysical therapyKnee osteoarthritisOutcomes researchbusinessRMD Open
researchProduct

The Therapeutic Effects of Whole-Body Vibration in Patients With Fibromyalgia. A Randomized Controlled Trial

2021

Fibromyalgia is a chronic pain disease with few effective therapeutic options. We evaluated the efficacy of a 12-weeks therapy program that involves the use of whole body vibration in patients with fibromyalgia. The experimental group (N = 20 patients) participated in a neuromuscular training with a rotational whole body vibration platform for 12 weeks. The control group (N = 20 patients) received no physiotherapy treatment. The following variables were assessed before, after and 3 months after the therapy program: Fibromyalgia impact questionnaire, pain intensity, quality of life, sensitivity measurements (pressure pain thresholds, vibration thresholds), motor function tasks (Berg scale, 6…

medicine.medical_specialtyIsometric exerciselaw.invention03 medical and health sciences0302 clinical medicineQuality of lifeRandomized controlled triallawFibromyalgiamedicineWhole body vibrationRC346-429Original ResearchBalance (ability)030203 arthritis & rheumatologybusiness.industryTherapeutic effectChronic painbalancewhole-body vibrationmedicine.diseaseNeurologymotor performancePhysical therapyfibromyalgiapain sensitivityNeurology. Diseases of the nervous systemNeurology (clinical)business030217 neurology & neurosurgeryFrontiers in Neurology
researchProduct

OARSI/OMERACT Initiative to Define States of Severity and Indication for Joint Replacement in Hip and Knee Osteoarthritis. An OMERACT 10 Special Inte…

2011

Objective.To define pain and physical function cutpoints that would, coupled with structural severity, define a surrogate measure of “need for joint replacement surgery,” for use as an outcome measure for potential structure-modifying interventions for osteoarthritis (OA).Methods.New scores were developed for pain and physical function in knee and hip OA. A cross-sectional international study in 1909 patients was conducted to define data-driven cutpoints corresponding to the orthopedic surgeons’ indication for joint replacement. A post hoc analysis of 8 randomized clinical trials (1379 patients) evaluated the prevalence and validity of cutpoints, among patients with symptomatic hip/knee OA.…

medicine.medical_specialtyJoint replacementmedicine.medical_treatmentImmunologyPROGRESSIONOsteoarthritisPLACEBO-CONTROLLED TRIAL2-YEARArticlelaw.inventionRADIOGRAPHIC FEATURES03 medical and health sciencesDOUBLE-BLIND0302 clinical medicinePhysical medicine and rehabilitationRheumatologyRandomized controlled triallawSeverity of illnessPost-hoc analysismedicinePHYSICAL-FUNCTIONImmunology and Allergy030212 general & internal medicine030203 arthritis & rheumatologyHip surgery3-YEARbusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/NeurosciencePAINASSOCIATIONmedicine.diseaseArthroplasty3. Good healthGLUCOSAMINE SULFATEOSTEOARTHRITIS SEVERITY PAIN FUNCTION STRUCTURE OUTCOME MEASURE placebo-controlled trial double-blind radiographic features glucosamine sulfate physical-function progression pain association 3-year 2-yearOrthopedic surgeryPhysical therapybusiness
researchProduct

Leishmaniasis and Biologic Therapies for Rheumatologic Diseases

2010

In his article in Seminars in Arthritis and Rheumatism,Furst (1) provides an accurate analysis of the infec-tions that are related to the use of biologic therapiesfor rheumatoid arthritis. We would like to addLeishma-niaspp to the list of the infectious agents that can causedisease during the course of biologic therapies.

medicine.medical_specialtyLeishmaniasis Rheumatologic DiseasesAnesthesiology and Pain MedicineRheumatologybusiness.industryBiologic therapiesmedicineLeishmaniasismedicine.diseasebusinessDermatologySeminars in Arthritis and Rheumatism
researchProduct

OP0090 THE OCCURRENCE OF SUBCLINICAL AND CLINICAL ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS, RESULTS FROM THE 3-YEAR, MULTICENTER, PROSPECTIVE, OBSERVA…

2019

Background The systemic inflammatory process and the “traditional” cardiovascular (CV) risk factors could synergize the enhancement of CV burden in rheumatoid arthritis (RA) [1]. Objectives To assess the occurrence and the predictive factors of subclinical and clinical atherosclerosis in patients with RA. Methods During 2015, consecutive patients, admitted to Italian Rheumatology Units, were assessed in GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort [2]. After that, patients were followed-up in a 3-year, prospective, observational study, assessing the occurrence of subclinical (carotid and/or peripheral arteries atherosclerotic lesions detected by ultrasou…

medicine.medical_specialtyLow dosagebusiness.industryviruseseducationmedicine.diseaseInternal medicineSubclinical atherosclerosisRheumatoid arthritisCohortUltrasound imagingmedicineObservational studyIn patientbusinessSubclinical infectionOral Presentations
researchProduct

Assessment of etanercept efficacy in the treatment of psoriatic arthritis: ultrasonography of Achilles tendon

2015

medicine.medical_specialtyMEDLINEArthritisDermatologyAchilles TendonEtanerceptEtanercept030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritis0302 clinical medicinemedicineHumansUltrasonography030203 arthritis & rheumatologyAchilles tendonbusiness.industryArthritis Psoriaticmedicine.diseaseDermatologymedicine.anatomical_structureInfectious DiseasesUltrasonographybusinessmedicine.drugHuman2708
researchProduct

The effectiveness of intra-articular injectionc of Hyalubrix combined with exercise therapy in the tratment of hip osteoarthritis

2017

Purpose. Osteoarthritis (OA) is the most common joint disorder in the elderly, causing significant pain which negatively affects mobility and quality ol liie. The aim of the study was to assess the effectiveness of ultrasound Ímage-guided intra-articular injections of Hyalubrix@ combined with exercise therapy in the treatment of hip osteoarthritis. Methods. This was a single site, prospèctive, open-fabel, Investigator-initiated study. Forty patients rilere enrolled and received three ultrasound image.guided injections of Hyalubrix@, 45 days apart, combined with three sessions a week of physícal therapy (proprioceptive rehabilitation of the lower limbs; gait training; balance training) up to…

medicine.medical_specialtyMaterials Science (miscellaneous)medicine.medical_treatmentOsteoarthritis03 medical and health sciences0302 clinical medicineQuality of lifeGait trainingmedicinephysical therapy. [hip osteoafihrosts; viscosupplementation; hyaluronic acid]030203 arthritis & rheumatology030222 orthopedicsRehabilitationProprioceptionbusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaUltrasoundhyaluronic acid: physical therapy.hip osteoafihrostExercise therapymedicine.diseasePhysical therapyOriginal ArticleViscosupplementationbusinessviscosupplementation
researchProduct

Hyperpigmentation of hard palate induced by chloroquine therapy

2017

The antimalarials are one of the most commonly prescribed drugs for conditions such as lupus erythematosus and rheumatoid arthritis, and the side effects, though infrequent, are well known. The antimalarial agent chloroquine diphosphate usually causes pigmentary changes in the oral mucosa characterized by a bluish-grey to black discolorations mainly in the hard palate. Considering only the hard palate hyperpigmentation caused by chloroquine, to the best of our knowledge, only 13 cases have been reported in the English language literature. We described an additional case of palate hyperpigmentation related to the chronic use of chloroquine diphosphate in a 60-year-old Mexican woman. Although…

medicine.medical_specialtyMedication historyCase Report03 medical and health sciences0302 clinical medicineChloroquinemedicineAntimalarial AgentOral mucosaAdverse effectGeneral DentistryOral Medicine and Pathologybusiness.industry030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]HyperpigmentationDermatologymedicine.anatomical_structure030220 oncology & carcinogenesisRheumatoid arthritisUNESCO::CIENCIAS MÉDICASHard palatemedicine.symptombusinessmedicine.drug
researchProduct

New approaches in the treatment of Adamantiades-Behçet's disease.

2005

Purpose of review To update clinicians on the recent advances in the treatment of Adamantiades-Behcet's disease. Recent findings Interferon-α-2a and infliximab have proved able to induce prompt remission in the vast majority of Adamantiades-Behcet's patients with DMARD-resistant uveoretinitis. Efficacy of interferon-α-2a has also been reported for mucocutaneous lesions, arthritis, and (more anecdotally) for neuro-Behcet, while results from small case series suggest that infliximab is beneficial for mucocutaneous lesions and (more anecdotally) for arthritis and gastro-intestinal manifestations. Two cases of neuro-Behcet treated with infliximab showed a complete resolution. Finally, in a rand…

medicine.medical_specialtyMucocutaneous zoneArthritisBehcet's diseaseDiseaseInterferon alpha-2Receptors Tumor Necrosis Factorlaw.inventionEtanerceptEtanerceptRheumatologyRandomized controlled triallawAntibodies Monoclonal; Behcet Syndrome; Chaperonin 60; Humans; Immunoglobulin G; Immunologic Factors; Interferon-alpha; Receptors Tumor Necrosis Factor; Recombinant ProteinsmedicineHumansImmunologic FactorsIFN-α2abusiness.industryBehcet SyndromeAntibodies MonoclonalInterferon-alphaChaperonin 60medicine.diseaseDermatologyeye diseasesInfliximabAdamantiades-Behçet's diseaseInfliximabRecombinant Proteinsstomatognathic diseasesImmunoglobulin GImmunologyTumour necrosis factorbusinessTolerizationUveitismedicine.drugCurrent opinion in rheumatology
researchProduct